Search Options Stock News and Analysis from Schaeffer's

VRTX Plummets After Ditching Experimental Drug

https://www.schaeffersresearch.com/content/news/2021/06/11/vrtx-plummets-after-ditching-experimental-drug

6/11/2021 10:25 AM

The shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) are down 11.7% at $191.50 at last check, after the company announced an experimental drug it was developing to treat a rare genetic cond...

3 Earnings Winners to Watch Today

https://www.schaeffersresearch.com/content/news/2020/01/31/3-earnings-winners-to-watch-today

1/31/2020 10:53 AM

Earnings have been in focus all week on Wall Street, and that's continuing today, with a number of big names making notable moves after their quarterly reports. Leading the way of course is Amazon.co...

Crispr Therapeutics Stock Pops on Vertex Stake

https://www.schaeffersresearch.com/content/news/2018/12/24/crispr-therapeutics-stock-pops-on-vertex-stake

12/24/2018 11:43 AM

Crispr Therapeutics AG (NASDAQ:CRSP) is trading up 9.9% at $24.98 today, after it was revealed Friday evening that cystic fibrosis specialist Vertex Pharmaceuticals (VRTX) took a 10.1% stake in the ge...

2 Healthcare Stocks To Avoid This Month

https://www.schaeffersresearch.com/content/analysis/2018/11/01/2-healthcare-stocks-to-avoid-next-month

11/1/2018 12:44 PM

Biotech name Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) and medical device stock Boston Scientific Corporation (NYSE:BSX) both had subpar Octobers, pulling back amid the broader market sell-off. And...

https://www.schaeffersresearch.com/content/options/2018/10/18/puts-popular-as-vertex-pharmaceuticals-extends-pullback

10/18/2018 3:06 PM

Proteostasis Therapeutics (PTI) scored a big win after reporting positive data for its cystic fibrosis drug in an early stage study. In response, sector peer Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX...

PEOPLE ALSO SEARCH FOR

-intraday-options-activity